SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001549595-23-000039
Filing Date
2023-07-13
Accepted
2023-07-13 16:18:23
Documents
13
Period of Report
2023-07-13
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K nrix-20230713.htm   iXBRL 8-K 28153
2 EX-99.1 nrix-20230713xexx991.htm EX-99.1 90014
  Complete submission text file 0001549595-23-000039.txt   266501

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20230713.xsd EX-101.SCH 1901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20230713_lab.xml EX-101.LAB 26849
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20230713_pre.xml EX-101.PRE 14116
7 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20230713_htm.xml XML 3016
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 231086963
SIC: 2834 Pharmaceutical Preparations